Moleculin Biotech Inc (MBRX): Stock Price

This chart illustrating the price evolution of MBRX visualizes the dynamics of Moleculin Biotech, Inc., which develops anti-cancer solutions through partnerships with scientific centers. Funding is based on investments and grants, while returns at the level of 7.85 are expected from the sale of treatments for complex tumors. The company is currently actively completing phase II trials of new molecules to combat leukemia.

Price Performance Chart: Moleculin Biotech (MBRX) for 07/04/2022 - 11/14/2026

Summary analytical data breakdowns for moleculin.com (MBRX)

- stock value and consensus price forecast:

Price Chart Moleculin Biotech Inc|MBRX - Consensus Target

- stock exchange capitalization data:

Market Capitalization MBRX|MBRX - Total Company Value

- book capitalization information:

Net Assets per Single Share Moleculin Biotech|MBRX - Accounting Value of Company|Market Cap to Net Assets Ratio moleculin.com|MBRX - Total Business Assets

- debt obligations and liquidity statistics:

- company profitability and valuation multiples indicators:

MBRX - Company Net Income|Expected Profit Moleculin Biotech, Inc.|MBRX - Market Cap to Earnings|Forward P/E Multiple Moleculin Biotech|MBRX - Price to Net Income Growth Ratio|Enterprise Value to EBITDA Ratio Moleculin Biotech Inc|MBRX - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Moleculin Biotech|MBRX - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months moleculin.com|MBRX - Earnings per share trend in current year|Net earnings per share growth forecast for next year Moleculin Biotech, Inc.

- sales volume and revenue information:

MBRX - Company Revenue|Projected Sales Volume moleculin.com|MBRX - P/S Multiple|Forward Price-to-Revenue Multiple Moleculin Biotech Inc

Summary company analytics:Moleculin Biotech, Inc.

Signature product of Moleculin Biotech, Inc.

The development of software robots for the express validation of oncological data makes Moleculin Biotech, Inc. (MBRX) sensitive to news flow. Analyzing this snapshot of stock quotes, an investor observes a market equilibrium between supply and demand, where the amplitude of fluctuations reflects the real-time assessment of risks and profit expectations, allowing for the determination of speculative volatility and the overall resilience of the asset.

Competitors of Moleculin Biotech, Inc.